Novo Nordisk A/S

NVO

N/A

NYSEBiotechnology🇩🇰Europe78.6K employees

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 20, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Semaglutide 1 mg	Phase 3	Diabetes Mellitus, Type 2	-
rosiglitazone	Phase 3	Diabetes	-
insulin lispro	Phase 3	Diabetes	-
Semaglutide J	Phase 3	Diabetes Mellitus, Type 2	-
biphasic insulin aspart 50	Phase 3	Diabetes	-
turoctocog alfa pegol (N8-GP)	Phase 3	Haemophilia A	-
exenatide	Phase 3	Diabetes	-
DPP-4 inhibitor	Phase 3	Diabetes	-
NNC0365-3769 (Mim8)	Phase 3	Haemophilia A	-
Insulin Glargine 100U/mL	Phase 3	Diabetes Mellitus, Type 2	-
Norditropin®	Phase 3	Growth Hormone Deficiency in Children	-
sitagliptin	Phase 3	Diabetes	-
repaglinide and metformin combination tablet	Phase 3	Diabetes	-
Placebo (matched to Cagrilintide)	Phase 3	Overweight	-
nonacog beta pegol	Phase 3	Congenital Bleeding Disorder	-
glimepiride	Phase 3	Diabetes	-
Insulin glargine U100	Phase 3	Diabetes Mellitus, Type 2	-
repaglinide	Phase 3	Diabetes	-
biphasic human insulin 50	Phase 3	Diabetes	-
Semaglutide 1.0 mg	Phase 3	Obesity	-
NPH insulin	Phase 3	Diabetes	-
biphasic human insulin	Phase 3	Diabetes	-
Insuline glargine U100 (reduced)	Phase 3	Diabetes Mellitus, Type 2	-
insulin human	Phase 3	Diabetes	-
inhaled human insulin	Phase 3	Diabetes	-
Etavopivat	Phase 3	Sickle Cell Disease	-
Placebo semaglutide	Phase 3	Overweight	-
Ziltivekimab	Phase 3	Heart Failure	-
pioglitazone	Phase 3	Diabetes	-
Canagliflozin	Phase 3	Diabetes	-
sulfonylurea	Phase 3	Diabetes	-
Oral semaglutide	Phase 3	Diabetes Mellitus, Type 2	-
Placebo cagrilintide	Phase 3	Obesity	-
Faster-acting insulin aspart	Phase 3	Diabetes	-
Insulin Icodec	Phase 3	Diabetes Mellitus, Type 2	-
Semaglutide 0.5 mg	Phase 3	Diabetes	-
somapacitan	Phase 3	Adult Growth Hormone Deficiency	-
human soluble insulin	Phase 3	Diabetes	-
human insulin	Phase 3	Diabetes	-
oral anti-diabetic drug	Phase 3	Diabetes	-
Mim8	Phase 3	Haemophilia A	-
IcoSema	Phase 3	Type 2 Diabetes	-
insulin detemir	Phase 3	Diabetes	-
Semaglutide 2.4 mg	Phase 3	Obesity	-
Dulaglutide	Phase 3	Diabetes	-
somatropin	Phase 3	Growth Hormone Disorder	-
Cagrilintide	Phase 3	Obesity or Overweight	-
insulin NPH	Phase 3	Diabetes	-
Semaglutide	Phase 3	Obesity	-
Placebo (semaglutide)	Phase 3	Overweight	-
insulin aspart	Phase 3	Diabetes	-
insulin degludec/liraglutide	Phase 3	Diabetes	-
insulin degludec	Phase 3	Diabetes	-
catridecacog	Phase 3	Congenital Bleeding Disorder	-
liraglutide	Phase 3	Diabetes	-
insulin degludec/insulin aspart	Phase 3	Diabetes	-
Placebo	Phase 3	Non-alcoholic Steatohepatitis	-
metformin	Phase 3	Diabetes	-
insulin glargine	Phase 3	Diabetes	-
Tirzepatide	Phase 3	Diabetes Mellitus, Type 2	-
biphasic insulin aspart	Phase 3	Diabetes	-
turoctocog alfa pegol	Phase 3	Congenital Bleeding Disorder	-
Cagrilintide 2.4 mg	Phase 2	Diabetes Mellitus, Type 2	-
CDR132L	Phase 2	Heart Failure	-
NNC109-0012	Phase 2	Inflammation	-
NNC6019-0001	Phase 2	Transthyretin Amyloid Cardiomyopathy (ATTR CM)	-
Concizumab	Phase 2	Congenital Bleeding Disorder	-
insulin 338 (GIPET I)	Phase 2	Diabetes	-
NNC0662-0419	Phase 2	Overweight	-
NNC0090-2746	Phase 2	Diabetes	-
Turoctocog alfa	Phase 2	Haemostasis	-
Placebo (insulin 287)	Phase 2	Diabetes Mellitus, Type 2	-
oral placebo	Phase 2	Diabetes	-
activated recombinant human factor VII	Phase 2	Acquired Bleeding Disorder	-
biphasic insulin aspart 30	Phase 2	Diabetes	-
eptacog alfa (activated)	Phase 2	Acquired Bleeding Disorder	-
NNC0174-0833	Phase 2	Overweight	-
NNC0114-0006	Phase 2	Diabetes	-
NNC0194-0499	Phase 2	Alcohol-related Liver Disease	-
biphasic insulin aspart 70	Phase 2	Diabetes	-
DCR-PHXC	Phase 2	Primary Hyperoxaluria Type 1 (PH1)	-
NNC126-0083	Phase 2	Growth Hormone Disorder	-
Placebo (Mim8)	Phase 2	Healthy Volunteers	-
EX1000	Phase 2	Diabetes	-
NNC0487-0111	Phase 2	Obesity	-
NNC0519-0130	Phase 2	Diabetes Mellitus, Type 2	-
NNC0194 0499 50 mg/mL	Phase 2	Non-alcoholic Steatohepatitis	-
Fast-acting insulin aspart	Phase 2	Diabetes Mellitus, Type 1	-
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg	Phase 2	Obesity	-
biphasic human insulin 30	Phase 2	Diabetes	-
recombinant interleukin-21	Phase 2	Cancer	-
NNC 0151-0000-0000	Phase 2	Inflammation	-
NDec - oral decitabine-tetrahydrouridine	Phase 2	Sickle Cell Disease	-

Catalyst Timeline

10 upcoming, 0 past

⭐Phase 3Next

Cagrilintide Phase 3 Results Expected

Feb 20, 2026Cagrilintide

Primary completion for Cagrilintide trial (NCT06221969) in Type 2 Diabetes

Source

⭐Phase 3

Tirzepatide Phase 3 Results Expected

Feb 20, 2026Tirzepatide

Primary completion for Tirzepatide trial (NCT06221969) in Type 2 Diabetes

Source

⭐Phase 3

Semaglutide Phase 3 Results Expected

Feb 20, 2026Semaglutide

Primary completion for Semaglutide trial (NCT06221969) in Type 2 Diabetes

Source

⭐Phase 3

Concizumab Phase 3 Results Expected

Apr 21, 2026Concizumab

Primary completion for Concizumab trial (NCT05135559) in Haemophilia A and B With and Without Inhibitors

Source

⭐Phase 3

Semaglutide Phase 3 Results Expected

Jun 2, 2026Semaglutide

Primary completion for Semaglutide trial (NCT06534411) in Diabetes Mellitus, Type 2

Source

⭐Phase 3

Tirzepatide Phase 3 Results Expected

Jun 2, 2026Tirzepatide

Primary completion for Tirzepatide trial (NCT06534411) in Diabetes Mellitus, Type 2

Source

⭐Phase 3

Cagrilintide Phase 3 Results Expected

Jun 2, 2026Cagrilintide

Primary completion for Cagrilintide trial (NCT06534411) in Diabetes Mellitus, Type 2

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Sep 3, 2026Placebo

Primary completion for Placebo trial (NCT06118281) in Cardiovascular Risk

Source

⭐Phase 3

Ziltivekimab Phase 3 Results Expected

Sep 3, 2026Ziltivekimab

Primary completion for Ziltivekimab trial (NCT06118281) in Cardiovascular Risk

Source

Phase 2

NNC0662-0419 Phase 2 Results Expected

Dec 1, 2026NNC0662-0419

Primary completion for NNC0662-0419 trial (NCT07184632) in Overweight

Source

Regulatory Approvals

NVO News

Novo Nordisk A/S

NVO

N/A

NYSEBiotechnology🇩🇰Europe78.6K employees

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 20, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Semaglutide 1 mg	Phase 3	Diabetes Mellitus, Type 2	-
rosiglitazone	Phase 3	Diabetes	-
insulin lispro	Phase 3	Diabetes	-
Semaglutide J	Phase 3	Diabetes Mellitus, Type 2	-
biphasic insulin aspart 50	Phase 3	Diabetes	-
turoctocog alfa pegol (N8-GP)	Phase 3	Haemophilia A	-
exenatide	Phase 3	Diabetes	-
DPP-4 inhibitor	Phase 3	Diabetes	-
NNC0365-3769 (Mim8)	Phase 3	Haemophilia A	-
Insulin Glargine 100U/mL	Phase 3	Diabetes Mellitus, Type 2	-
Norditropin®	Phase 3	Growth Hormone Deficiency in Children	-
sitagliptin	Phase 3	Diabetes	-
repaglinide and metformin combination tablet	Phase 3	Diabetes	-
Placebo (matched to Cagrilintide)	Phase 3	Overweight	-
nonacog beta pegol	Phase 3	Congenital Bleeding Disorder	-
glimepiride	Phase 3	Diabetes	-
Insulin glargine U100	Phase 3	Diabetes Mellitus, Type 2	-
repaglinide	Phase 3	Diabetes	-
biphasic human insulin 50	Phase 3	Diabetes	-
Semaglutide 1.0 mg	Phase 3	Obesity	-
NPH insulin	Phase 3	Diabetes	-
biphasic human insulin	Phase 3	Diabetes	-
Insuline glargine U100 (reduced)	Phase 3	Diabetes Mellitus, Type 2	-
insulin human	Phase 3	Diabetes	-
inhaled human insulin	Phase 3	Diabetes	-
Etavopivat	Phase 3	Sickle Cell Disease	-
Placebo semaglutide	Phase 3	Overweight	-
Ziltivekimab	Phase 3	Heart Failure	-
pioglitazone	Phase 3	Diabetes	-
Canagliflozin	Phase 3	Diabetes	-
sulfonylurea	Phase 3	Diabetes	-
Oral semaglutide	Phase 3	Diabetes Mellitus, Type 2	-
Placebo cagrilintide	Phase 3	Obesity	-
Faster-acting insulin aspart	Phase 3	Diabetes	-
Insulin Icodec	Phase 3	Diabetes Mellitus, Type 2	-
Semaglutide 0.5 mg	Phase 3	Diabetes	-
somapacitan	Phase 3	Adult Growth Hormone Deficiency	-
human soluble insulin	Phase 3	Diabetes	-
human insulin	Phase 3	Diabetes	-
oral anti-diabetic drug	Phase 3	Diabetes	-
Mim8	Phase 3	Haemophilia A	-
IcoSema	Phase 3	Type 2 Diabetes	-
insulin detemir	Phase 3	Diabetes	-
Semaglutide 2.4 mg	Phase 3	Obesity	-
Dulaglutide	Phase 3	Diabetes	-
somatropin	Phase 3	Growth Hormone Disorder	-
Cagrilintide	Phase 3	Obesity or Overweight	-
insulin NPH	Phase 3	Diabetes	-
Semaglutide	Phase 3	Obesity	-
Placebo (semaglutide)	Phase 3	Overweight	-
insulin aspart	Phase 3	Diabetes	-
insulin degludec/liraglutide	Phase 3	Diabetes	-
insulin degludec	Phase 3	Diabetes	-
catridecacog	Phase 3	Congenital Bleeding Disorder	-
liraglutide	Phase 3	Diabetes	-
insulin degludec/insulin aspart	Phase 3	Diabetes	-
Placebo	Phase 3	Non-alcoholic Steatohepatitis	-
metformin	Phase 3	Diabetes	-
insulin glargine	Phase 3	Diabetes	-
Tirzepatide	Phase 3	Diabetes Mellitus, Type 2	-
biphasic insulin aspart	Phase 3	Diabetes	-
turoctocog alfa pegol	Phase 3	Congenital Bleeding Disorder	-
Cagrilintide 2.4 mg	Phase 2	Diabetes Mellitus, Type 2	-
CDR132L	Phase 2	Heart Failure	-
NNC109-0012	Phase 2	Inflammation	-
NNC6019-0001	Phase 2	Transthyretin Amyloid Cardiomyopathy (ATTR CM)	-
Concizumab	Phase 2	Congenital Bleeding Disorder	-
insulin 338 (GIPET I)	Phase 2	Diabetes	-
NNC0662-0419	Phase 2	Overweight	-
NNC0090-2746	Phase 2	Diabetes	-
Turoctocog alfa	Phase 2	Haemostasis	-
Placebo (insulin 287)	Phase 2	Diabetes Mellitus, Type 2	-
oral placebo	Phase 2	Diabetes	-
activated recombinant human factor VII	Phase 2	Acquired Bleeding Disorder	-
biphasic insulin aspart 30	Phase 2	Diabetes	-
eptacog alfa (activated)	Phase 2	Acquired Bleeding Disorder	-
NNC0174-0833	Phase 2	Overweight	-
NNC0114-0006	Phase 2	Diabetes	-
NNC0194-0499	Phase 2	Alcohol-related Liver Disease	-
biphasic insulin aspart 70	Phase 2	Diabetes	-
DCR-PHXC	Phase 2	Primary Hyperoxaluria Type 1 (PH1)	-
NNC126-0083	Phase 2	Growth Hormone Disorder	-
Placebo (Mim8)	Phase 2	Healthy Volunteers	-
EX1000	Phase 2	Diabetes	-
NNC0487-0111	Phase 2	Obesity	-
NNC0519-0130	Phase 2	Diabetes Mellitus, Type 2	-
NNC0194 0499 50 mg/mL	Phase 2	Non-alcoholic Steatohepatitis	-
Fast-acting insulin aspart	Phase 2	Diabetes Mellitus, Type 1	-
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg	Phase 2	Obesity	-
biphasic human insulin 30	Phase 2	Diabetes	-
recombinant interleukin-21	Phase 2	Cancer	-
NNC 0151-0000-0000	Phase 2	Inflammation	-
NDec - oral decitabine-tetrahydrouridine	Phase 2	Sickle Cell Disease	-